European Free-to-Air TV Platforms Endorse Intertrust ExpressPlay XCA for Broadcast Content Protection
13.9.2018 15:00:00 EEST | Business Wire | Press release
Free-to-air TV platforms Freesat and Tivù have today endorsed Intertrust’s ExpressPlay XCA™ conditional access system (CAS) at IBC.
As the inventor of Digital Rights Management (DRM) technology, Intertrust introduced ExpressPlay XCA (XCA), a modern CAS that is based on their popular open standard Marlin technology, which was originally founded by Intertrust, Panasonic, Philips, Sony, and Samsung. ExpressPlay XCA leverages hardware security in smart TV and set-top box chipsets to provide world-class content security and full CAS capabilities – including head-end integration at a fraction of the cost of a legacy CAS.
“For years, TV operators have had to manage a tricky balance between set-top box manufacturers and CAS providers to deliver premium TV, often leaving themselves at the mercy of CAS vendors. Meanwhile broadband TV providers use easy-to-integrate DRM with far less overhead,” said Talal G. Shamoon, Intertrust’s chief executive officer. “With today’s TV chipsets, smart TVs and set-top boxes, we can remove legacy problems with our Marlin DRM-based XCA while reducing costs and time-to-market, and increasing choice.”
With increasing competition from the Internet, traditional TV operators are embracing economies of scale provided by modern technology. In response to smart TV manufacturers readily integrating DRM systems into their OTT stack, Intertrust created XCA to provide broadcasters with a simple way to reduce their costs.
“As Freesat expands its connected product range, we sought a cost efficient, open alternative to traditional CAS,” said Andy Carr Director of CE @ Freesat. “XCA provides us with industry approved content security across a broad range of devices. As our service continues to grow, Intertrust becomes a key partner for us protecting the best possible high-value entertainment experience for our customers.”
To protect and manage content, XCA technology is used in TV platforms across Europe, India, China, Japan, and the United States. Its advanced DRM software engine efficiently protects broadcast streams, resulting in a future proof, open technology that is flexible and cost effective.
“Our viewers are the most important element in the equation,” said Alberto Sigismondi, Tivù chief executive officer. “With XCA, we could provide our viewers with a range of content choice across traditional TV platforms and set-top boxes, but also bridge the gap between the interests of Italy’s broadcasters.”
Intertrust also announced at IBC that Vestel, Europe’s second largest TV manufacturer will incorporate XCA into their smart TVs. Vestel joins a growing community of device makers who support Marlin-based technologies around the world.
About Intertrust
Intertrust provides trusted computing products and services to leading global corporations – from mobile, CE and IoT manufacturers, to service providers, and enterprise software platform companies. These products include the world’s leading digital rights management (DRM), software tamper resistance, and technologies to enable private data exchanges for various verticals including energy, entertainment, retail/marketing, automotive, fintech, and IoT.
Founded in 1990, Intertrust is headquartered in Silicon Valley with regional offices in London, Tokyo, Mumbai, Bangalore, Hyderabad, Beijing, Seoul, Riga, and Tallinn. The Company has a legacy of invention, and its fundamental contributions in the areas of computer security and digital trust are globally recognized. Intertrust holds hundreds of patents that are key to Internet security, trust, and privacy management components of operating systems, trusted mobile code and networked operating environments, web services, and cloud computing.
Additional information is available at intertrust.com, or follow us on Twitter or LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005407/en/
Contact information
Intertrust Technologies Corporation
Nishtha Sharma, +91 981-932-6284
nishthas@intertrust.com
or
Actual
Agency
Brian Regan, +1 908-399-7161
brian.regan@actual.agency
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom